StemCells Launches First Cell Culture Medium To Enable Derivation Of True Rat Embryonic Stem Cells

(Comment on this article at http://www.financialwire.net/2010/01/27/stemcells-launches-first-cell-culture-medium-to-enable-derivation-of-true-rat-embryonic-stem-cells/)

January 27, 2010 (FinancialWire) -- StemCells, Inc. (NASDAQ: STEM) said the launch of GS1-R(TM), the first commercially available medium to enable the derivation, maintenance and growth of true (germline competent) rat embryonic stem cells. GS1-R, the latest addition to the company's SC Proven line of specialty cell culture products, is expected to have significant utility in the creation of genetically engineered rat models of human disease for use in academic, medical and pharmaceutical research.

The rat is a valuable tool in drug discovery. Both mice and rats are used by scientists as models for human disease. However, because rats are physiologically more similar to humans than are mice, rat models can be better suited for assessing drug efficacy and toxicity. To date, efforts to model certain human diseases using rats have been hindered by a lack of the true rat ES cells needed to genetically engineer precise disease models. GS1-R will help scientists overcome this barrier as it provides the cell culture conditions necessary to consistently generate true rat ES cell lines.

The proprietary, breakthrough technology behind GS1-R was first published in December 2008 in the peer-reviewed journal Cell 1,2 after academic researchers in the United Kingdom and the United States succeeded in deriving the first true rat ES cells. StemCells, Inc. owns exclusive rights to the rat ES cell technology described in this publication and the media formulation used to create these rat pluripotent cell lines.-

The defined, serum-free GS1-R media formulation contains selective small molecule inhibitors that act to eliminate differentiation-inducing signals and promote cell survival, enabling the long-term maintenance of true germline competent rat ES cells in a pluripotent state. For more information about GS1-R and SC Proven cell culture products, interested parties are invited to visit www.scproven.com.

StemCells, Inc. is focused on the development and commercialization of cell-based technologies. In its cellular medicine programs, StemCells is targeting diseases of the central nervous system and liver.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network's "FirstAlert(tm) Daily" (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

http://www.financialwire.net

Related terms: academic, cellular, community, conference, disease, equity, media, medical, medicine, nasdaq, nervous system, pharmaceuticals, products, research, south carolina, standards, technology, utilities